Clinical Study of CD70-targeted CAR-T Therapy for Advanced/Advanced Renal Cancer

Summary

This is a phase I clinical study to evaluate the safety and tolerability of CAR-T in patients with advanced/metastatic renal cell carcinoma, and to obtain the maximum tolerated dose of CAR-T and phase II Recommended dose.

Timeline

Start

2021-12-31

Primary completion

2023-12-31

Completion

2024-12-31

Drugs

Indications